Check Before You Invest : Bharat Immunologicals & Biologicals Corporation Ltd

Snapshot

Q.1 Which industry/sub-sector does Bharat Immunologicals & Biologicals Corporation Ltd belong to?

Bharat Immunologicals & Biologicals Corporation Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Bharat Immunologicals & Biologicals Corporation Ltd a good quality company?

Bharat Immunologicals & Biologicals Corporation Ltd is a quality company, based on a 10-year financial track record.

Q.3 Is Bharat Immunologicals & Biologicals Corporation Ltd undervalued or overvalued?

Bharat Immunologicals & Biologicals Corporation Ltd appears Fair, as its key valuation ratios are in line with their past averages.

Q.4 Is Bharat Immunologicals & Biologicals Corporation Ltd a good buy now?

Bharat Immunologicals & Biologicals Corporation Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd revenue growth is -43.1% for FY-2023, which is below its 5-year CAGR of 5.09%, indicating slower growth.

Q.2 Return on capital employed (ROCE) of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Return on capital employed is -25.63% for FY-2023, which is below its 5-year historical median of -21.87%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.3 Return on Asset of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Return on Asset is -9.41%, which is in line with its 5-year historical median of -8.97%, indicating stable asset utilization efficiency.

Q.4 Return on Equity (ROE) of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Return on equity is 0% for FY-2023, which is above its 5-year historical median of -17%, indicating the business is making better use of its shareholders capital.

Q.5 Cash conversion cycle of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Cash conversion cycle is 209 days, above its 5-year historical median of 153 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.25	0.59
ROE	-	-17
ROCE	-25.63	-21.87
Cash Conversion Cycle	209 days	153 days

Q.6 Gross Profit margin of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Gross profit margin which is the profit after deduction of direct costs, is -49.5% for FY-2023, which is below its 5-year median of -20.9%, indicating decreasing margins.

Q.7 Operating Profit Margin of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -35.61% for FY-2023, which is below its 5-year median of -15.56% indicating decreasing margins.

Q.8 Net Profit Margin of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Net Profit Margin is -37.3% for FY-2023, is below with its 5-year median of -15.28%, indicating decreasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin	-49.5	-20.9
Operating Profit Margin	-35.61	-15.56
Net Profit Margin	-37.3	-15.28

Q.9 Debt to Equity ratio of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Debt-to-Equity ratio is -3.05, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Bharat Immunologicals & Biologicals Corporation Ltd?

Bharat Immunologicals & Biologicals Corporation Ltd Debt to cash flow from operations is 6.45, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Bharat Immunologicals & Biologicals Corporation Ltd?

Promoters hold 59.25% of the Bharat Immunologicals & Biologicals Corporation Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Bharat Immunologicals & Biologicals Corporation Ltd vs industry peers?

Bharat Immunologicals & Biologicals Corporation Ltd revenue CAGR is 5.09%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-43.1	8.3
Gross Profit Growth	0	14.7
Operating Profit Growth	0	11.4
Net Profit Growth	0	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.25	0.81
ROE	-	9.49
ROCE	-25.63	11.91
Cash Conversion Cycle (days)	209.06	85

Valuation & price assessment

Q.1 Stock return of Bharat Immunologicals & Biologicals Corporation Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -1.5% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	-1.5%	-18.2%	-10.2%	-24.1%

Q.3 Valuation ratios of Bharat Immunologicals & Biologicals Corporation Ltd vs historical?

The current P/E is higher that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	-	-6.47	31.09
Price to Book	-	-3.86	2.85
Price to Sales	1.67	2.27	2.79
EV to EBITDA	-9.32	-11.76	15.87

Check more companies

6. Wockhardt

7. Pfizer

8. Piramal Pharma

9. Acutaas Chemicals

10. Astrazeneca Pharma I

Check trending companies

1. Tata Elxsi Ltd.

2. Shree Cement Ltd.

3. Amara Raja Energy & Mobility Ltd.

4. Vishal Mega Mart Ltd.

5. Acme Solar Holdings Ltd.